Carnegie Capital Asset Management LLC Has $6.97 Million Stake in Pfizer Inc. (PFE)

Carnegie Capital Asset Management LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 31.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 160,140 shares of the biopharmaceutical company’s stock after acquiring an additional 38,133 shares during the quarter. Carnegie Capital Asset Management LLC’s holdings in Pfizer were worth $6,970,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. New England Professional Planning Group Inc. grew its holdings in shares of Pfizer by 2.0% during the 2nd quarter. New England Professional Planning Group Inc. now owns 224,595 shares of the biopharmaceutical company’s stock worth $8,156,000 after purchasing an additional 4,395 shares in the last quarter. Oppenheimer & Co. Inc. grew its holdings in shares of Pfizer by 6.8% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 771,105 shares of the biopharmaceutical company’s stock worth $27,976,000 after purchasing an additional 49,206 shares in the last quarter. Institute for Wealth Management LLC. grew its holdings in shares of Pfizer by 7.2% during the 2nd quarter. Institute for Wealth Management LLC. now owns 64,472 shares of the biopharmaceutical company’s stock worth $2,349,000 after purchasing an additional 4,344 shares in the last quarter. British Airways Pensions Investment Management Ltd grew its holdings in shares of Pfizer by 402.3% during the 2nd quarter. British Airways Pensions Investment Management Ltd now owns 361,722 shares of the biopharmaceutical company’s stock worth $13,123,000 after purchasing an additional 289,711 shares in the last quarter. Finally, Brown Advisory Inc. grew its holdings in shares of Pfizer by 3.3% during the 2nd quarter. Brown Advisory Inc. now owns 1,277,210 shares of the biopharmaceutical company’s stock worth $46,337,000 after purchasing an additional 41,337 shares in the last quarter. Institutional investors and hedge funds own 68.61% of the company’s stock.

Shares of PFE stock opened at $41.78 on Friday. The company has a current ratio of 1.57, a quick ratio of 1.33 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $248.71 billion, a P/E ratio of 13.93, a P/E/G ratio of 2.39 and a beta of 0.76. Pfizer Inc. has a one year low of $34.32 and a one year high of $46.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 29th. The biopharmaceutical company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.01. The company had revenue of $13.98 billion for the quarter, compared to analyst estimates of $13.92 billion. Pfizer had a return on equity of 26.02% and a net margin of 20.79%. The business’s revenue was up 2.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.62 earnings per share. Research analysts expect that Pfizer Inc. will post 2.86 earnings per share for the current fiscal year.

Pfizer declared that its board has approved a share repurchase program on Friday, December 14th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to buy up to 3.8% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s board believes its shares are undervalued.

Several analysts have recently weighed in on PFE shares. ValuEngine lowered Pfizer from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Citigroup reissued a “neutral” rating and set a $41.00 price objective on shares of Pfizer in a report on Wednesday, February 20th. Cantor Fitzgerald reissued a “buy” rating and set a $53.00 price objective on shares of Pfizer in a report on Tuesday, December 11th. Atlantic Securities reissued a “buy” rating and set a $54.00 price objective on shares of Pfizer in a report on Tuesday, November 27th. Finally, Credit Suisse Group reissued a “neutral” rating and set a $45.00 price objective on shares of Pfizer in a report on Thursday, December 20th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $44.89.

In other Pfizer news, insider Mikael Dolsten sold 149,553 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $43.55, for a total value of $6,513,033.15. Following the transaction, the insider now owns 390,097 shares of the company’s stock, valued at $16,988,724.35. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Dawn Rogers sold 15,002 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $42.98, for a total value of $644,785.96. Following the completion of the transaction, the executive vice president now directly owns 28,722 shares in the company, valued at approximately $1,234,471.56. The disclosure for this sale can be found here. In the last three months, insiders sold 308,826 shares of company stock worth $13,346,258. Insiders own 0.06% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2019/03/17/carnegie-capital-asset-management-llc-has-6-97-million-stake-in-pfizer-inc-pfe.html.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

See Also: Dow Jones Industrial Average (DJIA)

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply